Bone-turnover markers in fracture healing

Journal of Bone and Joint Surgery - Series B

Volumn 92, Issue 3, 2010, Pages 329-334

  Cox, G ^a   Einhorn, T A ^a,b   Tzioupis, C ^a   Giannoudis, P V ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; COLLAGEN; REGULATOR PROTEIN;

BIOCHEMISTRY; BONE MATRIX; BONE TURNOVER; CLINICAL PRACTICE; DISEASE COURSE; FRACTURE HEALING; HUMAN; METABOLIC BONE DISEASE; METABOLIC DISORDER; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; PSEUDARTHROSIS; QUANTITATIVE ANALYSIS; REVIEW; TRABECULAR BONE;

BIOLOGICAL MARKERS; BONE REMODELING; BONE RESORPTION; FRACTURE HEALING; HUMANS;

EID: 77649230665     PISSN: 0301620X     EISSN: None     Source Type: Journal    
DOI: 10.1302/0301-620X.92B3.22787     Document Type: Review

References (48)

1. Civitelli R, Armamento-Villareal R, Napoli N. Bone turnover markers: understanding their value in clinical trials and clinical practice. Osteoporos Int 2009;20:843-51.
2. Leeming DJ, Alexandersen P, Karsdal MA, et al. An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice. Eur J Clin Pharmacol 2006;62:781-92.
3. Watts NB. Clinical utility of biochemical markers of bone remodelling. Clin Chem 1999;45:1359-68.
4. Kurland ES, Cosman F, McMahon DJ, et al. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000;85:3069-76.
5. Nenonen A, Cheng S, Ivaska KK, et al. Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res 2005;20:1804-12.
6. Alvarez L, Guañabens N, Peris P, et al. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease. J Bone Miner Res 1995;10:458-65.
7. Bone HG. The future of osteoporosis diagnosis and therapy. Ann Ital Med Int 1992;7(3 Suppl):166-70.
8. Veitch SW, Findlay SC, Hamer AJ, et al. Changes in bone mass and bone turnover following tibial shaft fracture. Osteoporos Int 2006;17:364-72.
9. Hanson DA, Weis MA, Bollen AM, et al. A specific immunoassay for monitoring human bone resorption: quantification of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 1992;7:1251-8.
10. Garnero P, Ferreras M, Karsdal MA, et al. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 2003;18:859-67.
11. Stoffel K, Engler H, Kuster M, Riesen W. Changes in biochemical markers after lower limb fractures. Clin Chem 2007;53:131-4.
12. Joerring S, Krogsgaard M, Wilbek H, Jensen LT. Collagen turnover after tibial fractures. Arch Orthop Trauma Surg 1994;113:334-6.
13. Kurdy NM, Bowles S, Marsh DR, Davies A, France M. Serology of collagen types I and III is normal healing of tibial shaft fractures. J Orthop Trauma 1998;12:122-6.
14. Emami A, Larsson A, Petrén-Mallmin M, Larsson S. Serum bone markers after intramedullary fixed tibial fractures. Clin Orthop 1999;368:220-9.
15. Ohishi T, Takahashi M, Kushida K, et al. Changes in biochemical markers during fracture healing. Arch Orthop Trauma Surg 1998;118:126-30.
16. Karsdal MA, Henriksen K, Sørensen MG, et al. Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption. Am J Pathol 2005;166:467-76.
17. Holzer G, Noske H, Lang T, Holzer L, Willinger U. Soluble cathepsin K: a novel marker for the prediction of nontraumatic fractures? Lab Clin Med 2005;146:13-17.
18. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001;142:5050-5.
19. Li J, Sarosi I, Yan XQ, et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 2000;97:1566-71.
20. Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat Rev Genet 2003;4:638-49.
21. Arai F, Miyamoto T, Ohneda O, et al. Commitment and differentiation of osteoclast precursor cells by the sequential expression of C-Fms and receptor activator of nuclear factor kb (rank) receptors. J Exp Med 1999;190:1741-54.
22. Tanko LB, Mouritzen U, Lehmann HJ, et al. Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different sub optimally dosed treatment regimens. Bone 2003;32:687-93.
23. Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med 2001;79:243-53.
24. Carter DH, Sloan P, Aaron JE. Immunolocalization of collagen types I and III, tenascin, and fibronectin in intramembranous bone. J Histochem Cytochem 1991;39:599-606.
25. Joerring S, Jensen LT, Andersen GR, Johansen JS. Types I and III procollagen extension peptides in serum respond to fracture in humans. Arch Orthop Trauma Surg 1992;11:265-7.
26. Bowles SA, Kurdy N, Davis AM, France MW. Changes in serum bone-specific alkaline phosphatase following tibial fracture. Ann Clin Biochem 1997;34:690-1.
27. Harwood PJ, Giannoudis PV. Application of bone morphogenetic proteins in orthopaedic practice: their efficacy and side effects. Expert Opin Drug Saf 2005;4:75-89.
28. Dimitrou R, Dahabreh Z, Katsoulis E, et al. Application of recombinant BMP-7 on persistent upper and lower limb non-unions. Injury 2005;36(Suppl 4):51-9.
29. Giannoudis PV, Tzioupis C. Clinical applications of BMP-7: the UK perspective. Injury 2005;36(Suppl 3):47-50.
30. Govender S, Csimma C, Genant HK, et al. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg [Am] 2002;84-A:2123-34.
31. Ristiniemi J, Flinkkilä T, Hyvönen P, et al. RhBMP-7 accelerates the healing in distal tibial fractures treated by external fixation. J Bone Joint Surg [Br] 2007;89-B:265-72.
32. Ivaska KK, Gerdhem P, Akesson K, Garnero P, Obrant KJ. Effect of fracture on bone turnover markers: a longitudinal study comparing marker levels before and after injury in 113 elderly women. J Bone Miner Res 2007;22:1155-64.
33. Obrant KJ. Trabecular bone changes in the greater trochanter after fracture of the femoral neck. Acta Orthop Scand 1998;55:78-82.
34. Harada S, Rodan GA. Control of osteoblast function and regulation of bone mass. Nature 2003;423:349-55.
35. Halleen JM. Tartrate-resistant acid phosphatase 5B is a specific and sensitive marker of bone resorption. Anticancer Res 2003;23:1027-9.
36. Halleen JM, Ylipahkala H, Alatalo SL, et al. Serum tartate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density. Calcif Tissue Int 2002;71:20-5.
37. Bradley EW, Oursler MJ. Osteoclast culture and resorption assays. Methods Mol Biol 2008;455:19-35.
38. Kim JG, Kim JH, Kim JY, et al. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women. Menopause 2007;14:913-18.
39. Hermann M, Klitscher D, Georg T, et al. Different kinetics of bone markers in normal and delayed fracture healing of long bones. Clin Chem 2002;48:2263-6.
40. Oni OO, Mahabir JP, Iqbal SJ, Gregg PJ. Serum osteocalcin and total alkaline phosphatase levels as prognostic indicators in tibial shaft fractures. Injury 1989;20:37-8.
41. Qvist P, Christgau S, Pedersen BJ, Schlemmer A, Christiansen C. Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTX): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone 2002;31:57-61.
42. Schlemmer A, Hassager C, Alexandersen P, et al. Circadian variation in bone resorption is not related to serum cortisol. Bone 1997;21:83-8.
43. Schlemmer A, Hassager C. Acute fasting diminishes the circadian rhythm of biochemical markers of bone resorption. Eur J Endocrinol 1999;140:332-7.
44. Henriksen DB, Alexandersen P, Byrjalsen I, et al. Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2. Bone 2004;34:140-7.
45. Nyman MT, Paavolainen P, Forsius S, Lamberg-Allardt C. Clinical evaluation of fracture healing by serum osteocalcin and alkaline phosphatase. Ann Chir Gynaecol 1991;80:298-93.
46. Chesnut CH III. Sources of biological bone market variability. In: Eastell R, Baumann M, Hoyle NR, Wieczorek L, eds. Bone markers: biomechanical and clinical perspectives. London: Martin Dunitz, 2001:119-12.
47. Claudon A, Vergnaud P, Valverde C, et al. New automated multiplex assay for bone turnover markers in osteoporosis. Clin Chem 2008;54:1554-63.
48. Zimmerman G, Henle P, Küsswetter M, et al. TGF-beta1 as a marker of delayed fracture healing. Bone 2005;36:779-85.